Immunomodulatory adjuvant therapy in severe community-acquired pneumonia
- 23 May 2014
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Respiratory Medicine
- Vol. 8 (5), 587-596
- https://doi.org/10.1586/17476348.2014.927736
Abstract
Severe pneumonia has a high mortality (38.2%) despite evidence-based therapy. Rising rates of antimicrobial resistance increase the urgency to develop new treatment strategies. Multiple adjuvant therapies for pneumonia have been investigated but none are currently licensed. Profound immune dysregulation occurs in patients with severe infection. An initial hyper-inflammatory response is followed by a secondary hypo-inflammatory response with 'immune-paralysis'. There is focus on the development of immunostimulatory agents to improve host ability to combat primary infection and reduce secondary infections. Successful treatments must be targeted to immune response; promising biomarkers exist but have not yet reached common bedside practice. We explore evidence for adjuvant therapies in community-acquired pneumonia. We highlight novel potential treatment strategies using a broad-based search strategy to include publications in pneumonia and severe sepsis. We explore reasons for the failure to develop effective adjuvant therapies and highlight the need for targeted therapy specific to immune activity.Keywords
This publication has 90 references indexed in Scilit:
- Immunoactivating Peptide P4 Augments Alveolar Macrophage Phagocytosis in Two Diverse Human PopulationsAntimicrobial Agents and Chemotherapy, 2013
- Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsisCritical Care, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Effects of Recombinant Human Interleukin 7 on T-Cell Recovery and Thymic Output in HIV-Infected Patients Receiving Antiretroviral Therapy: Results of a Phase I/IIa Randomized, Placebo-Controlled, Multicenter StudyClinical Infectious Diseases, 2012
- Immunotherapy with a Combination of Intravenous Immune Globulin and P4 Peptide Rescues Mice from Postinfluenza Pneumococcal PneumoniaAntimicrobial Agents and Chemotherapy, 2011
- The Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsis*Critical Care Medicine, 2010
- Understanding the Inflammatory Cytokine Response in Pneumonia and SepsisArchives of Internal Medicine, 2007
- Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*Critical Care Medicine, 2006
- Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic MechanismsNature Reviews Drug Discovery, 2005